Epigral Ltd Hits Intraday Low Amidst Significant Price Pressure

Intraday Price Movement and Market Context

On 1 Feb 2026, Epigral Ltd, a Specialty Chemicals company, experienced significant price pressure with its stock falling by 7.1% intraday to Rs 965, the lowest level recorded in the past year. The day’s decline of 7.48% notably outpaced the Sensex’s fall of 2.17%, reflecting a pronounced underperformance. The stock’s one-day performance of -7.38% contrasts sharply with the Sensex’s -1.88% movement, signalling a more acute negative sentiment towards Epigral relative to the broader market.

The Sensex itself reversed sharply after a positive start, opening 119.19 points higher before tumbling 1,904.56 points to trade at 80,484.41. This broad market weakness contributed to the downward pressure on Epigral’s shares, which also lagged its Specialty Chemicals sector by 5.84% on the day.

Technical Indicators and Moving Averages

Epigral’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained downward momentum and a lack of near-term support levels. The stock’s failure to hold above these averages contrasts with the Sensex, which, despite trading below its 50-day moving average, still maintains a 50DMA above its 200DMA, indicating a more stable medium-term trend for the benchmark index.

Such technical weakness in Epigral’s chart is consistent with the stock’s deteriorating performance over multiple time frames, reinforcing the current negative sentiment among market participants.

Performance Trends Over Various Time Frames

Epigral Ltd’s recent performance trends highlight sustained weakness relative to the Sensex. Over the past week, the stock declined by 9.73%, compared to the Sensex’s 1.00% fall. The one-month performance shows a sharper drop of 21.94%, while the Sensex fell by 4.67% in the same period. Over three months, Epigral’s share price has plummeted by 42.98%, significantly underperforming the Sensex’s 4.36% decline.

Year-to-date, Epigral’s stock is down 21.10%, whereas the Sensex has declined by 5.28%. The one-year performance gap is even more pronounced, with Epigral falling 46.56% while the Sensex gained 5.16%. Over three years, Epigral’s stock has decreased by 6.71%, contrasting with the Sensex’s 35.67% rise. The stock has shown no gains over five and ten-year horizons, remaining flat at 0.00%, while the Sensex has appreciated by 74.40% and 224.57%, respectively.

Mojo Score and Market Capitalisation Grade

Epigral Ltd currently holds a Mojo Score of 31.0, categorised as a Sell grade. This represents an improvement from its previous Strong Sell rating, which was downgraded on 26 Dec 2025. The company’s Market Cap Grade stands at 3, indicating a relatively modest market capitalisation within its sector. These metrics reflect the ongoing challenges faced by the stock in regaining investor confidence amid the prevailing market conditions.

Sector and Market Sentiment

The Specialty Chemicals sector, to which Epigral belongs, has experienced mixed performance today, with Epigral underperforming the sector by 5.84%. Meanwhile, the NIFTY PSU index hit a new 52-week high, underscoring the divergence within the broader market segments. The sharp reversal in the Sensex after a positive opening has contributed to a cautious market sentiment, with investors reacting to broader macroeconomic factors and sector-specific developments.

Summary of Price Pressure and Market Dynamics

Epigral Ltd’s sharp decline to Rs 965 intraday, a fresh 52-week low, reflects intensified selling pressure amid a broadly negative market environment. The stock’s underperformance relative to both the Sensex and its sector highlights the immediate pressures weighing on its price. Trading below all major moving averages further emphasises the prevailing bearish momentum.

While the broader market experienced a steep correction after an initial positive start, Epigral’s share price reacted more severely, indicating heightened sensitivity to current market conditions. The company’s Mojo Score and Market Cap Grade reinforce the cautious stance adopted by investors, as reflected in the stock’s performance across multiple time frames.

Overall, the combination of technical weakness, sector underperformance, and adverse market sentiment has culminated in Epigral Ltd’s shares hitting their day low, underscoring the challenges faced in the current trading session.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →